TheraGauze™ Alone and Regranex®Gel 0.01% Plus TheraGauze™ in the Treatment of Wagner Stage I Diabetic Foot Ulcers
Status:
Unknown status
Trial end date:
2008-07-01
Target enrollment:
Participant gender:
Summary
Patients will be randomized to receive TheraGauze alone or with Regranex to treat diabetic
foot ulcer condition. The purpose of the study is provide the sponsor with pilot information
regarding the ability of TheraGauze to promote wound healing on its own and to examine
synergy with Regranex in the treatment of diabetic foot ulcers.